Leslie Busby, MD

Addressing issues such as congestive heart failure is important to providing safe care to patients with cancer.

Knowing whether repurposing old drugs helps patients with cancer is important, but it will take a concerted investment by public entities such as the National Institutes of Health to make this happen.

At the ASCO Annual Meeting, Asal Pilehvari, PhD, and colleagues presented a study evaluating the financial benefit of adding a CDK 4/6 inhibitor to hormone therapy for women with metastatic estrogen receptor-positive breast cancer in community settings.

Change Healthcare, owned by UnitedHealth Group, was targeted by cybercriminals, affecting 140 million Americans and costing $1 billion daily. Recovery efforts underscore the critical need for robust cybersecurity measures in healthcare.

A recent article pointed out that efforts to decrease low-value care often fall short. It asserted that a primary cause is physicians being financially motivated.

Leslie T. Busby, MD, discusses the shift from dose-dependent chemotherapy to the challenge of managing toxicities in biologic and targeted therapies, which are often erroneously developed using the maximum tolerated dose paradigm.

Currently, 6 separate bills have come out of congressional committees to increase pharmacy benefit managers regulation, with more transparency being the common factor.

Although drug shortages are not new, the number of drugs involved is increasing and resolutions seem to take longer, and oncology care is often affected by these shortages.